Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Bone Diseases

ClinicalTrials.gov lists 8,078 trials for Bone Diseases or a narrower condition beneath it. Novartis Pharmaceuticals has the most among industry and government lead sponsors, with 101.

MeSH D001847 Musculoskeletal Diseases C05
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 375 Phase 1/2 Phase 1/2 128 Phase 2 Phase 2 595 Phase 2/3 Phase 2/3 86 Phase 3 Phase 3 705 Phase 4 Phase 4 682 Not applicable Not applicable 2,823 Observational Observational 2,673 Phase 1 Phase 1 375 Phase 1/2 Phase 1/2 128 Phase 2 Phase 2 595 Phase 2/3 Phase 2/3 86 Phase 3 Phase 3 705 Phase 4 Phase 4 682 Not applicable Not applicable 2,823 Observational Observational 2,673

Trials per phase (log scale)

2 more sections with rows

176 of the 8,078 trials are tagged with Bone Diseases itself; the rest are tagged with a narrower condition beneath it.

Get the Bone Diseases report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Bone Diseases trials start? (37)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 14 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Expanded access, Unknown)

Top of scale: 499

1990: 1 trials (Phase 4 1) 1991: 6 trials (Observational 3, Phase 3 1, Phase 2/3 1, Phase 2 1) 1992: 3 trials (Phase 4 1, Phase 3 1, Phase 2 1) 1993: 7 trials (Observational 4, Not applicable 1, Phase 3 1, Phase 2 1) 1994: 9 trials (Observational 6, Not applicable 1, Phase 3 1, Phase 1 1) 1995: 12 trials (Observational 4, Phase 4 1, Phase 3 1, Phase 2 5, Phase 1 1) 1996: 14 trials (Observational 4, Not applicable 4, Phase 4 1, Phase 3 3, Phase 2 2) 1997: 20 trials (Observational 10, Not applicable 3, Phase 3 4, Phase 2 2, Phase 1/2 1) 1998: 33 trials (Observational 13, Not applicable 9, Phase 4 3, Phase 3 1, Phase 2 6, Phase 1/2 1) 1999: 47 trials (Observational 11, Not applicable 16, Phase 4 2, Phase 3 5, Phase 2 10, Phase 1 3) 2000: 59 trials (Observational 15, Not applicable 4, Phase 4 9, Phase 3 13, Phase 2/3 2, Phase 2 9, Phase 1 7) 2001: 66 trials (Observational 11, Not applicable 18, Phase 4 9, Phase 3 19, Phase 2/3 2, Phase 2 5, Phase 1/2 1, Phase 1 1) 2002: 99 trials (Observational 21, Not applicable 15, Phase 4 13, Phase 3 30, Phase 2/3 4, Phase 2 8, Phase 1/2 2, Phase 1 6) 2003: 133 trials (Observational 25, Not applicable 23, Phase 4 22, Phase 3 37, Phase 2/3 5, Phase 2 12, Phase 1/2 2, Phase 1 7) 2004: 163 trials (Observational 34, Not applicable 24, Phase 4 30, Phase 3 38, Phase 2/3 1, Phase 2 24, Phase 1/2 1, Phase 1 11) 2005: 146 trials (Observational 45, Not applicable 21, Phase 4 27, Phase 3 29, Phase 2/3 3, Phase 2 13, Phase 1/2 3, Phase 1 5) 2006: 219 trials (Observational 51, Not applicable 47, Phase 4 43, Phase 3 38, Phase 2/3 1, Phase 2 17, Phase 1/2 4, Phase 1 18) 2007: 222 trials (Other 1, Observational 72, Not applicable 42, Phase 4 30, Phase 3 31, Phase 2/3 3, Phase 2 25, Phase 1/2 4, Phase 1 14) 2008: 227 trials (Observational 63, Not applicable 44, Phase 4 39, Phase 3 30, Phase 2/3 6, Phase 2 23, Phase 1/2 10, Phase 1 12) 2009: 237 trials (Observational 76, Not applicable 58, Phase 4 21, Phase 3 28, Phase 2/3 4, Phase 2 30, Phase 1/2 3, Phase 1 17) 2010: 235 trials (Observational 72, Not applicable 65, Phase 4 19, Phase 3 33, Phase 2/3 4, Phase 2 22, Phase 1/2 5, Phase 1 15) 2011: 244 trials (Observational 81, Not applicable 66, Phase 4 23, Phase 3 28, Phase 2/3 2, Phase 2 25, Phase 1/2 3, Phase 1 16) 2012: 273 trials (Observational 97, Not applicable 82, Phase 4 27, Phase 3 22, Phase 2 21, Phase 1/2 10, Phase 1 14) 2013: 262 trials (Observational 96, Not applicable 89, Phase 4 25, Phase 3 18, Phase 2/3 1, Phase 2 19, Phase 1/2 3, Phase 1 11) 2014: 306 trials (Observational 99, Not applicable 103, Phase 4 28, Phase 3 23, Phase 2/3 3, Phase 2 24, Phase 1/2 6, Phase 1 20) 2015: 343 trials (Other 2, Observational 111, Not applicable 115, Phase 4 30, Phase 3 29, Phase 2/3 4, Phase 2 28, Phase 1/2 7, Phase 1 17) 2016: 304 trials (Observational 94, Not applicable 115, Phase 4 32, Phase 3 24, Phase 2/3 3, Phase 2 24, Phase 1 12) 2017: 350 trials (Observational 104, Not applicable 134, Phase 4 24, Phase 3 29, Phase 2/3 5, Phase 2 31, Phase 1/2 6, Phase 1 17) 2018: 390 trials (Observational 134, Not applicable 156, Phase 4 27, Phase 3 25, Phase 2/3 5, Phase 2 22, Phase 1/2 5, Phase 1 16) 2019: 458 trials (Observational 168, Not applicable 172, Phase 4 23, Phase 3 33, Phase 2/3 3, Phase 2 27, Phase 1/2 9, Phase 1 23) 2020: 371 trials (Observational 154, Not applicable 129, Phase 4 14, Phase 3 16, Phase 2/3 1, Phase 2 31, Phase 1/2 9, Phase 1 17) 2021: 485 trials (Observational 190, Not applicable 187, Phase 4 30, Phase 3 29, Phase 2/3 2, Phase 2 27, Phase 1/2 5, Phase 1 15) 2022: 462 trials (Observational 157, Not applicable 221, Phase 4 28, Phase 3 11, Phase 2/3 5, Phase 2 20, Phase 1/2 1, Phase 1 19) 2023: 499 trials (Observational 194, Not applicable 223, Phase 4 26, Phase 3 20, Phase 2/3 2, Phase 2 11, Phase 1/2 2, Phase 1 21) 2024: 474 trials (Observational 171, Not applicable 223, Phase 4 20, Phase 3 21, Phase 2/3 3, Phase 2 22, Phase 1/2 6, Phase 1 8) 2025: 447 trials (Observational 144, Not applicable 220, Phase 4 25, Phase 3 13, Phase 2/3 5, Phase 2 19, Phase 1/2 7, Phase 1 14)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 396
2025 447
2024 474
2023 499
2022 462
2021 485
2020 371
2019 458
2018 390
2017 350

Showing 10 of 37 earlier years.

Start your 14-day trial Email me all 37 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 480 trials starting in 2026 and about 460 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 526 trials still running at the 2026-10-09 snapshot; registered median of 25 months across 4,875 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Bone Diseases trials in? (10)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 375
Phase 1/2 128
Phase 2 595
Phase 2/3 86
Phase 3 705
Phase 4 682
Not applicable 2,823
Observational 2,673
Expanded access 9
Unknown 2

How many Bone Diseases trials are recruiting? (12)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 351
Recruiting 847
Enrolling by invitation 106
Active, not recruiting 339
Available 3

Showing 5 of 12 statuses.

Start your 14-day trial Email me all 12 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Bone Diseases trials? (6)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Novartis Pharmaceuticals 101
Pfizer 83
Amgen 80
Zimmer Biomet 75
Eli Lilly and Company 66

Showing 5 of 6 sponsors.

Start your 14-day trial Email me all 6 sponsors as a PDF

Which drugs are being tested for Bone Diseases? (4)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
DENOSUMAB 120
Calcium/Vitamin D 51
INFLIXIMAB 39
Calcium-vitamin D3 32

Interventions as named in the registry (11)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
somatropin AQ 115
acid Zoledronic 113
Transdermal Teriparatide 111
Alendronate 20 mg 93
1=Etanercept 67

Showing 5 of 11 interventions.

Start your 14-day trial Email me all 11 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Bone Diseases trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Pneumonia 1,797 218
Osteoarthritis 1,332 156
All Fractures 860 1
Atrial fibrillation 803 112
Cerebrovascular accident 674 97

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Bone Diseases? (248)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Feasibility and safety of sailing based rehabilitation for rare skeletal disorders using wearable sensors and patient reported outcomes. Scientific reports 2025 Yes
Recommended calcium intake in adults and children with chronic kidney disease-a European consensus statement. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2024 Yes
A Comprehensive Review of Bone Health in a Child: From Birth to Adulthood. The Journal of the American Academy of Orthopaedic Surgeons 2024 Yes
Association Between Structural Change Over Eighteen Months and Subsequent Symptom Change in Middle-Aged Patients Treated for Meniscal Tear. Arthritis care & research 2023 Yes
Muscle strength and osteoarthritis of the knee: a systematic review and meta-analysis of longitudinal studies. Skeletal radiology 2023 Yes

Showing 5 of 248 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Sub-conditions in MeSH (20)

MeSH descendants one level down with at least one trial, most trials first.

+10 more sub-conditions

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages